Michelle Carr, Author at BioTuesdays

Developments

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics Holdings (NASDAQ:EKSO) has announced that it has successfully demonstrated initial proof-of-concept in integrating new AI-enabled capabilities across its portfolio of Enterprise Health and Personal Health...

June 18, 2025

Developments

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...

June 10, 2025

Developments

NeoGenomics introduces PanTracer genomic profiling tests at ASCO 2025

NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...

May 28, 2025

Executive Moves

Accomplished medtech industry veteran, Laurie Vertuccio, joins Profound Medical as VP of Global Marketing

Laurie Vertuccio has joined Profound Medical (NASDAQ:PROF; TSX:PRN) as Vice President of Global Marketing. The TULSA procedure, performed using Profound’s TULSA-PRO system, has the potential of becoming a mainstream...

May 27, 2025

Developments

Vaccine publishes study demonstrating benefits of PharmaJet’s Tropis needle-free system

Closely held PharmaJet announced the publication of a study in the top-tier journal Vaccine, which demonstrates the benefits of the company’s Tropis needle-free system compared to needle and syringe (N/S) for...

May 1, 2025

Developments

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Closely held eGenesis and OrganOx announced that the FDA has cleared the IND application for EGEN-5784—a human-compatible, genetically engineered porcine liver—designed for use in combination with the OrganOx...

April 15, 2025

Developments

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Aditxt (NASDAQ:ADTX) announced that a Mayo Clinic study has confirmed ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD)—a key autoantigen connected to multiple autoimmune conditions including Type 1...

April 14, 2025

Developments

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

During a recent episode of the Flagrant podcast hosted by Andrew Schulz and Akash Singh, investor and entrepreneur Chamath Palihapitiya offered a compelling example of how medical innovation can drive meaningful...

April 10, 2025

Executive Moves

Brian Donnelly joins Myriad as CCO

Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. Mr. Donnelly brings more than 20 years of leadership experience in healthcare...

April 8, 2025

Developments

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen. According to Attosa, it also plans to work with the FDA to advance additional...

March 11, 2025

Author - Michelle Carr

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

NeoGenomics introduces PanTracer genomic profiling tests at ASCO 2025

Accomplished medtech industry veteran, Laurie Vertuccio, joins Profound Medical as VP of Global Marketing

Vaccine publishes study demonstrating benefits of PharmaJet’s Tropis needle-free system

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

Brian Donnelly joins Myriad as CCO

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Subscribe